Literature DB >> 26611258

Increased x-ray attenuation in malignant vs. benign mediastinal nodes in an orthotopic model of lung cancer.

Paul Flechsig1, Peter Choyke, Clemens Kratochwil, Arne Warth, Gerald Antoch, Tim Holland Letz, Daniel Rath, Viktoria Eichwald, Peter E Huber, Hans-Ulrich Kauczor, Uwe Haberkorn, Frederik L Giesel.   

Abstract

PURPOSE: Staging of lung cancer is typically performed with fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET/CT); however, false positive PET scans can occur due to inflammatory disease. The CT scan is used for anatomic registration and attenuation correction. Herein, we evaluated x-ray attenuation (XRA) within nodes on CT and correlated this with the presence of malignancy in an orthotopic lung cancer model in rats.
METHODS: 1×10⁶ NCI-H460 cells were injected transthoracically in six National Institutes of Health nude rats and six animals served as controls. After two weeks, animals were sacrificed; lymph nodes were extracted and scanned with a micro-CT to determine their XRA prior to histologic analysis.
RESULTS: Median CT density in malignant lymph nodes (n=20) was significantly higher than benign lymph nodes (n=12; P = 0.018). Short-axis diameter of metastatic lymph nodes was significantly different than benign nodes (3.4 mm vs. 2.4 mm; P = 0.025). Area under the curve for malignancy was higher for density-based lymph node analysis compared with size measurements (0.87 vs. 0.7).
CONCLUSION: XRA of metastatic mediastinal lymph nodes is significantly higher than benign nodes in this lung cancer model. This suggests that information on nodal density may be useful when used in combination with the results of FDG-PET in determining the likelihood of malignant adenopathy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26611258      PMCID: PMC4712895          DOI: 10.5152/dir.2015.15220

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  24 in total

Review 1.  Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer.

Authors:  Ozcan Birim; A Pieter Kappetein; Theo Stijnen; Ad J J C Bogers
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

2.  High-resolution brain tumor visualization using three-dimensional x-ray phase contrast tomography.

Authors:  F Pfeiffer; O Bunk; C David; M Bech; G Le Duc; A Bravin; P Cloetens
Journal:  Phys Med Biol       Date:  2007-11-08       Impact factor: 3.609

Review 3.  FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review.

Authors:  Dirk Hellwig; Richrad P Baum; Carl Kirsch
Journal:  Nuklearmedizin       Date:  2009-01-14       Impact factor: 1.379

4.  Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition).

Authors:  Gerard A Silvestri; Michael K Gould; Mitchell L Margolis; Lynn T Tanoue; Douglas McCrory; Eric Toloza; Frank Detterbeck
Journal:  Chest       Date:  2007-09       Impact factor: 9.410

5.  Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis.

Authors:  Jiang Liu; Fiona Blackhall; Isolde Seiden-Long; Igor Jurisica; Roya Navab; Ni Liu; Nikolina Radulovich; Dennis Wigle; Muhajid Sultan; Jim Hu; Ming-Sound Tsao; Michael R Johnston
Journal:  Oncogene       Date:  2004-08-19       Impact factor: 9.867

6.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

Authors:  Niklaus G Schaefer; Thomas F Hany; Christian Taverna; Burkhardt Seifert; Katrin D M Stumpe; Gustav K von Schulthess; Gerhard W Goerres
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

8.  Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.

Authors:  K G Tournoy; S Maddens; R Gosselin; G Van Maele; J P van Meerbeeck; A Kelles
Journal:  Thorax       Date:  2007-08       Impact factor: 9.139

Review 9.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

Authors:  Eric M Toloza; Linda Harpole; Douglas C McCrory
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

Review 10.  Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis.

Authors:  Michael K Gould; Ware G Kuschner; Chara E Rydzak; Courtney C Maclean; Anita N Demas; Hidenobu Shigemitsu; Jo Kay Chan; Douglas K Owens
Journal:  Ann Intern Med       Date:  2003-12-02       Impact factor: 25.391

View more
  3 in total

1.  Role of CT Density in PET/CT-Based Assessment of Lymphoma.

Authors:  Paul Flechsig; Christina Walker; Clemens Kratochwil; Laila König; Andrei Iagura; Jan Moltz; Tim Holland-Letz; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

2.  Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients.

Authors:  Paul Flechsig; Philipp Frank; Clemens Kratochwil; Gerald Antoch; Daniel Rath; Jan Moltz; Michael Rieser; Arne Warth; Hans-Ulrich Kauczor; Lawrence H Schwartz; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

3.  Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.

Authors:  Paul Flechsig; Ramin Rastgoo; Clemens Kratochwil; Ole Martin; Tim Holland-Letz; Alexander Harms; Hans-Ulrich Kauczor; Uwe Haberkorn; Frederik L Giesel
Journal:  Mol Imaging Biol       Date:  2018-12       Impact factor: 3.488

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.